Neurotransmitters and Related Medications

Dopamine System

• Synthesis and metabolism: L-tyrosine → L-DOPA (via tyrosine hydroxylase) → dopamine (via DOPA decarboxylase) → norepinephrine → epinephrine. Dopamine is metabolized by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT).
• Anatomical pathways: Four major circuits include the nigrostriatal pathway (substantia nigra to striatum; motor control), mesolimbic pathway (ventral tegmental area to nucleus accumbens; reward/motivation), mesocortical pathway (ventral tegmental area to prefrontal cortex; cognition), and tuberoinfundibular pathway (hypothalamus to pituitary; prolactin inhibition).
• Receptor mechanisms: Five dopamine receptors (D1-D5) divided into D1-like (D1, D5; Gs-coupled, excitatory) and D2-like (D2, D3, D4; Gi-coupled, inhibitory) families mediate opposing effects on neuronal activity.

Serotonin (5-Hydroxytryptamine) System

• Synthesis and metabolism: L-tryptophan → 5-hydroxytryptophan (5-HTP, via tryptophan hydroxylase) → serotonin. Metabolized by MAO-A to 5-hydroxyindoleacetaldehyde (5-HIAL) then 5-hydroxyindoleacetic acid (5-HIAA), the latter excreted in urine as a diagnostic marker.
• Anatomical distribution: Dorsal raphe nucleus (mood, cognition, sleep) and median raphe nucleus (anxiety, reward) project widely to forebrain structures. Serotonin also present in gut (95% of body's serotonin).
• Receptor mechanisms: Seven serotonin receptor families (5-HT1 through 5-HT7) with multiple subtypes. 5-HT1A and 5-HT1B are inhibitory (Gi-coupled); 5-HT2A and 5-HT2C are excitatory (Gq-coupled); 5-HT3 is ligand-gated ion channel; 5-HT4, 5-HT6, 5-HT7 are Gs-coupled (excitatory).

Acetylcholine System

• Synthesis and metabolism: Acetyl-CoA + choline → acetylcholine (via choline acetyltransferase, ChAT). Rapidly hydrolyzed by acetylcholinesterase (AChE) in synaptic cleft and by butyrylcholinesterase in plasma.
• Central nervous system: Basal forebrain cholinergic system projects to cortex and hippocampus (cognition, memory, attention). Brainstem pedunculopontine and laterodorsal tegmental nuclei modulate arousal and REM sleep.
• Peripheral nervous system: Parasympathetic neuromuscular junction utilizes nicotinic receptors; parasympathetic autonomic functions use muscarinic receptors. Nicotinic receptors are ligand-gated ion channels (fast transmission); muscarinic receptors (M1-M5) are G-protein coupled (slow modulation).

Glutamate System

• Synthesis and metabolism: α-ketoglutarate (citric acid cycle intermediate) → glutamate (via transamination). Recycled between neurons and astrocytes via glutamate-glutamine shuttle. Excessive levels cause excitotoxicity through sustained depolarization.
• Receptor types: NMDA receptors (N-methyl-D-aspartate; ligand-gated ion channels requiring both glutamate AND glycine co-agonist, blocked by Mg2+ at rest), AMPA receptors, kainate receptors (all ionotropic; fast), and metabotropic glutamate receptors (G-protein coupled; slow modulation).
• Physiological role: Primary excitatory neurotransmitter; essential for synaptic plasticity, learning, and memory. Over-activation implicated in stroke, traumatic brain injury, epilepsy, and neurodegeneration.

GABA (γ-Aminobutyric Acid) System

• Synthesis and metabolism: Glutamate → GABA (via glutamic acid decarboxylase, GAD, requires pyridoxal-5-phosphate/vitamin B6). Metabolized by GABA transaminase (GABA-T) to succinic semialdehyde.
• Receptor mechanisms: GABAA receptors are ligand-gated chloride channels (fast inhibition; chloride influx → hyperpolarization). GABAB receptors are G-protein coupled (slow inhibition; activates K+ channels, inhibits Ca2+ channels). GABAC receptors are specialized retinal/spinal receptors.
• Functional significance: Primary inhibitory neurotransmitter in CNS; essential for seizure threshold, anxiety regulation, and motor control. GABAergic interneurons critical for network oscillations underlying consciousness.

Norepinephrine System

• Synthesis and metabolism: Dopamine → norepinephrine (via dopamine-β-hydroxylase). Metabolized by MAO and COMT to vanillylmandelic acid (VMA) and 3-methoxy-4-hydroxyphenylglycol (MHPG).
• Anatomical pathways: Locus coeruleus (brainstem) is primary source, projecting broadly to cortex, amygdala, and hippocampus. Regulates alertness, attention, fear conditioning, and stress response.
• Receptor mechanisms: α1 (Gq-coupled, excitatory), α2 (Gi-coupled, inhibitory), β1, β2, β3 (Gs-coupled, excitatory) subtypes with tissue-specific distributions.

Histamine System

• Synthesis and metabolism: L-histidine → histamine (via histidine decarboxylase). Metabolized by histamine N-methyltransferase (HNMT) to N-methylhistamine and by diamine oxidase (DAO) to imidazole acetic acid.
• Anatomical location: Tuberomammillary nucleus of hypothalamus projects to entire cortex. Primary role in circadian rhythm regulation, arousal, and appetite control.
• Receptor mechanisms: H1 receptors (Gq-coupled; sedation when blocked), H2 receptors (Gs-coupled; gastric acid), H3 receptors (Gi-coupled; feedback inhibition), H4 receptors (immune modulation).

Genetic Factors

• Catechol-O-methyltransferase (COMT) polymorphisms: Val158Met variant affects dopamine catabolism; homozygous Val individuals have higher dopamine catabolism, potentially contributing to cognitive differences and schizophrenia risk.
• Serotonin transporter (SERT) polymorphisms: Long (L) and short (S) alleles of 5-HTTLPR promoter region; S allele associated with depression, anxiety, and reduced treatment response to SSRIs.
• Monoamine oxidase genes: MAO-A and MAO-B polymorphisms affect neurotransmitter metabolism; low-activity MAO-A variants associated with increased impulsivity and violence risk in childhood maltreatment.
• Dopamine receptor variants: DRD2 and DRD3 polymorphisms implicated in addiction vulnerability, antipsychotic response, and parkinsonism risk.

Acquired Deficiencies

• Vitamin B6 deficiency: Required as pyridoxal phosphate cofactor for GAD (GABA synthesis) and tyrosine hydroxylase; deficiency impairs both inhibitory and dopaminergic tone.
• Vitamin B12/folate deficiency: Impairs methylation reactions affecting neurotransmitter synthesis and myelin formation; causes subacute combined degeneration.
• Tryptophan depletion: Dietary or secondary to carcinoid syndrome (excess conversion to 5-HT) reduces serotonin synthesis; causes carcinoid syndrome neuropsychiatric symptoms.
• Tyrosine deficiency: Rare but may occur with malnutrition; impairs dopamine and catecholamine synthesis.

Enzymatic Dysfunction

• Aromatic amino acid decarboxylase (AADC) deficiency: Genetic disorder preventing conversion of L-DOPA and 5-HTP to dopamine and serotonin; causes severe movement disorder and developmental delay.
• Monoamine oxidase deficiency: Brunner syndrome (MAO-A deficiency) causes behavioral abnormalities and selective serotonin elevation. MAO-B deficiency less clinically significant.
• Glutamic acid decarboxylase (GAD) autoimmunity: Anti-GAD65 and anti-GAD67 antibodies cause GABA synthesis impairment; associated with stiff-person syndrome, epilepsy, and autoimmune ataxia.
• Acetylcholinesterase inhibition: Genetic variants of butyrylcholinesterase (pseudocholinesterase deficiency) cause prolonged apnea after succinylcholine or mivacurium.

Transporter Dysfunction

• Vesicular monoamine transporter (VMAT2) dysfunction: Impaired packaging of dopamine/serotonin into vesicles; occurs with rotenone exposure (pesticide) and contributes to Parkinson's disease.
• Serotonin transporter (SERT) polymorphisms and downregulation: Reduced transporter expression decreases serotonin reuptake; associated with depression and SSRI responsiveness.
• Dopamine transporter (DAT) deficiency: Rare genetic condition causes hypokinetic movement disorder and dopamine accumulation in synaptic cleft.
• Choline transporter deficiency: Impairs acetylcholine synthesis; associated with myasthenic syndrome.

Dopamine Deficiency States (Hypokinetic Disorders)

• Cardinal symptoms: Bradykinesia (slow movement initiation), rigidity (resistance throughout movement arc), resting tremor (4-6 Hz pill-rolling tremor), postural instability, gait freezing, masked facies, hypophonia, micrographia.
• Parkinson's disease presentation: Unilateral motor features initially; progressive bilateral involvement over years. Non-motor features include hyposmia (loss of smell), REM sleep behavior disorder, constipation, depression, cognitive decline.
• Dopamine dysregulation: Anhedonia (inability to experience pleasure), decreased motivation, fatigue, bradyphrenia (slow cognition), depression with psychomotor retardation.

Dopamine Excess States (Hyperkinetic Disorders)

• Hyperkinetic movement disorders: Chorea (involuntary dance-like movements), ballismus (large-amplitude flinging movements), dystonia (sustained muscle contractions causing abnormal postures), tics (stereotyped, repetitive movements).
• Psychotic symptoms: Delusions (fixed false beliefs), hallucinations (perceptual distortions, classically auditory), disorganized speech/behavior, negative symptoms (apathy, anhedonia, alogia).
• Hypomanic/manic states: Elevated/expansive mood, grandiosity, decreased need for sleep, flight of ideas, psychomotor agitation, impulsive behavior, increased goal-directed activity.

Serotonin Deficiency

• Mood disturbances: Depressed mood, anhedonia, hopelessness, guilt, suicidal ideation; often accompanied by psychomotor retardation or agitation.
• Sleep dysfunction: Early morning awakening (terminal insomnia), hypersomnia, non-restorative sleep, circadian rhythm disruption.
• Cognitive symptoms: Difficulty concentrating, indecisiveness, poor memory, rumination, negative thought patterns.
• Physical manifestations: Appetite/weight changes (increase or decrease), fatigue, pain syndromes (fibromyalgia-like), gastrointestinal dysfunction.

Serotonin Excess (Serotonin Syndrome)

• Acute presentation: Agitation, confusion, restlessness, tremor, hypereflexia, muscle rigidity (particularly lower extremities and jaw), fever, diaphoresis, tachycardia, tachypnea.
• Severe manifestations: Rhabdomyolysis, disseminated intravascular coagulation (DIC), acute renal failure, cerebral edema, seizures, coma, cardiovascular collapse.
• Physical exam findings: Clonus (spontaneous and particularly inducible), myoclonus, hyperreflexia, pupillary dilation, flushed skin, hyperthermia.

Acetylcholine Deficiency (Cholinergic Insufficiency)

• Cognitive symptoms: Amnesia, confusion, disorientation, delirium, hallucinations (particularly visual), paranoia, agitation.
• Movement disorder: Akathisia (subjective restlessness with inability to remain still), dystonia, parkinsonism.
• Autonomic dysfunction: Mydriasis (pupillary dilation), dry mouth, urinary retention, constipation, tachycardia, reduced sweating.
• Classic presentation: Anticholinergic toxidrome - "hot as a hare, dry as a bone, red as a beet, mad as a hatter, blind as a bat" (mydriasis, anhidrosis, hyperthermia, delirium, vision loss).

Acetylcholine Excess (Cholinergic Toxicity)

• Muscarinic symptoms: SLUDGE syndrome - Salivation, Lacrimation, Urination, Defecation, GI upset, Emesis plus miosis (pinpoint pupils), bronchospasm, bradycardia, muscle weakness.
• Nicotinic symptoms: Fasciculations (visible muscle twitching), paralysis, respiratory failure.
• CNS manifestations: Confusion, anxiety, seizures, loss of consciousness, respiratory depression.

Glutamate Excess (Excitotoxicity)

• Acute stroke/TIA: Sudden focal neurological deficits (hemiparesis, hemianopia, aphasia, ataxia), altered mental status, headache; glutamate release from damaged neurons drives secondary excitotoxic injury.
• Traumatic brain injury: Initial mechanical injury followed by excitotoxic cascade; manifests as deteriorating consciousness, focal deficits, seizures.
• Seizures: Uncontrolled glutamate-driven excitation causes rhythmic muscle contractions, loss of consciousness, incontinence, postictal confusion.
• Neurodegenerative diseases: Chronic excitotoxicity in ALS, Huntington's, Parkinson's causes progressive motor/cognitive decline.

GABA Deficiency

• Seizure disorders: Breakthrough seizures (generalized tonic-clonic, focal, absence, myoclonic depending on location), status epilepticus (>5 minutes continuous seizure activity or cluster).
• Anxiety symptoms: Excessive worry, panic attacks (sudden-onset fear with autonomic discharge), insomnia, muscle tension, irritability.
• Movement abnormalities: Tremor, dystonia, hyperreflexia, spasticity.
• Hyperacusis/photophobia: Heightened sensitivity to sound and light due to reduced sensory gating.

Neurotransmitter syndromes are clinical diagnoses — laboratory testing supports, it does not confirm

• Serotonin syndrome: diagnose at the bedside using the Hunter Serotonin Toxicity Criteria (Dunkley), which require exposure to a serotonergic agent plus one of: spontaneous clonus; inducible clonus with agitation or diaphoresis; ocular clonus with agitation or diaphoresis; tremor with hyperreflexia; or hypertonia with temperature above 38°C plus ocular or inducible clonus. Onset is typically within hours of a dose increase or drug addition. Neuromuscular findings are greatest in the lower extremities.
• Neuroleptic malignant syndrome: DSM-5-TR frames this as a medication-induced condition requiring dopamine-antagonist exposure with hyperthermia, lead-pipe rigidity, autonomic instability, and altered sensorium evolving over days. Creatine kinase is markedly elevated, with leukocytosis and often low serum iron; obtain CK, renal function, electrolytes, and coagulation studies.
• Cholinergic crisis (organophosphate/carbamate): diagnosis is the toxidrome (miosis, bronchorrhea, fasciculations). Red blood cell acetylcholinesterase activity is the more accurate confirmatory assay; plasma butyrylcholinesterase is more sensitive but less specific. Never delay atropine awaiting results.
• Anticholinergic toxidrome: clinical — dry axillae, mydriasis, flushing, urinary retention, delirium with normal bowel sounds absent. ECG is mandatory to detect QRS prolongation implicating a sodium-channel-blocking agent such as a tricyclic.

Disease-level confirmation when a deficiency state is suspected

• Parkinson disease: diagnosed by the MDS Clinical Diagnostic Criteria — bradykinesia plus rest tremor or rigidity, with supportive levodopa responsiveness. Dopamine transporter SPECT (DaTscan) separates degenerative parkinsonism from essential or drug-induced tremor but cannot distinguish PD from atypical parkinsonism.
• Serotonin-secreting tumor: 24-hour urinary 5-HIAA is the classic confirmatory test for carcinoid syndrome.
• Catecholamine excess: plasma free metanephrines are the preferred initial test for pheochromocytoma; urinary VMA is the historical distractor.
• Antibody-mediated GABA/ACh failure: anti-GAD65 antibodies in stiff-person syndrome; acetylcholine receptor and MuSK antibodies in myasthenia gravis.

Immediate stabilization (any neurotransmitter toxidrome)

• Stop the offending agent and secure airway, breathing, circulation. Hyperthermia in serotonin syndrome and NMS is generated by sustained muscle activity, not a raised hypothalamic set point — antipyretics are useless; use external cooling, IV fluids, and paralysis with a non-depolarizing agent plus intubation if temperature is extreme.
• Benzodiazepines (e.g., lorazepam) are the universal first-line agent for agitation, rigidity, and autonomic hyperactivity in serotonin syndrome, NMS, stimulant toxicity, and alcohol/benzodiazepine withdrawal, since GABA-A potentiation opposes excess excitatory drive.

Syndrome-specific antidotes

• Serotonin syndrome: add cyproheptadine, a 5-HT2A antagonist, when benzodiazepines and supportive care are insufficient (oral/NG only).
• Neuroleptic malignant syndrome: dopamine agonist (bromocriptine) and/or direct muscle relaxant (dantrolene, which blocks ryanodine-receptor calcium release); restart dopaminergic therapy if NMS followed abrupt levodopa withdrawal.
• Anticholinergic delirium: physostigmine, a tertiary-amine cholinesterase inhibitor that crosses the blood-brain barrier — the American College of Medical Toxicology supports its use for pure antimuscarinic delirium but it is contraindicated with QRS widening or tricyclic overdose (asystole/seizure risk); treat those with sodium bicarbonate.
• Organophosphate poisoning: atropine titrated to drying of bronchial secretions (not to pupil size or heart rate) plus pralidoxime to reactivate acetylcholinesterase before aging.

Chronic disease-modifying pharmacology

• Depression: APA practice guidance places SSRIs (sertraline) first line; escalate by switching class (SNRI, bupropion, mirtazapine) or augmenting.
• Parkinson disease: AAN guidance favors carbidopa-levodopa for initial motor symptom control, with MAO-B inhibitors, COMT inhibitors, and dopamine agonists as adjuncts; deep brain stimulation of the subthalamic nucleus or globus pallidus interna is the definitive option for motor fluctuations.

Emergencies — recognize immediately

• Serotonin syndrome and NMS: sustained muscle contraction drives hyperthermia → rhabdomyolysis (markedly elevated CK, myoglobinuric acute kidney injury), DIC, and cardiovascular collapse. Signal findings: clonus and hyperreflexia (serotonin) versus lead-pipe rigidity with hyporeflexia (NMS).
• Cholinergic crisis: bronchorrhea and bronchospasm plus nicotinic diaphragmatic weakness cause respiratory failure — the actual cause of death, not bradycardia.
• Tricyclic overdose: sodium-channel blockade widens QRS and produces a terminal R wave in aVR, predicting ventricular arrhythmia and seizure.
• MAOI hypertensive crisis: tyramine-containing food or sympathomimetics release stored norepinephrine → severe headache, hypertension, intracranial hemorrhage.
• Abrupt benzodiazepine or alcohol cessation: loss of GABA-A tone unmasks glutamatergic excess → withdrawal seizures and delirium tremens.

Complications of chronic dopamine blockade

• Acute dystonia and akathisia: early nigrostriatal D2 blockade; treat with anticholinergics (benztropine) or beta blockade for akathisia.
• Tardive dyskinesia: chronic D2 blockade causes postsynaptic receptor upregulation/supersensitivity; orofacial choreoathetosis that may be irreversible. VMAT2 inhibitors are the targeted therapy.
• Hyperprolactinemia: tuberoinfundibular D2 blockade removes prolactin inhibition → galactorrhea, amenorrhea, gynecomastia, bone loss.
• Metabolic syndrome: H1 and 5-HT2C antagonism drives weight gain, dyslipidemia, and diabetes, especially with olanzapine and clozapine; clozapine additionally causes agranulocytosis, myocarditis, seizures, and severe constipation.

Complications of other agents

• SSRIs: SIADH with hyponatremia (elderly), bleeding from platelet serotonin depletion, sexual dysfunction, QT prolongation with citalopram, and a flu-like discontinuation syndrome with short-half-life agents such as paroxetine.
• Levodopa: peak-dose dyskinesias, wearing-off, orthostatic hypotension, hallucinations, and dopamine-agonist-associated impulse control disorders (gambling, hypersexuality).
• Anticholinergics: delirium, urinary retention, and falls in older adults — listed as potentially inappropriate by the AGS Beers Criteria.

• Clonus is the discriminator: hyperreflexia, inducible/ocular clonus, diarrhea, and mydriasis within hours of adding a serotonergic drug = serotonin syndrome. Diffuse lead-pipe rigidity with hyporeflexia and bradykinesia over days after a D2 antagonist = neuroleptic malignant syndrome. Both are hyperthermic; the reflexes decide.
• Best next step in serotonin syndrome: stop the drug, give a benzodiazepine, cool actively — then cyproheptadine. The common distractor is dantrolene, which belongs to NMS and malignant hyperthermia, not serotonin toxicity.
• Carbidopa does not cross the blood-brain barrier; it blocks peripheral DOPA decarboxylase, reducing nausea and orthostasis while increasing levodopa delivery to the brain. Examiners love this mechanism.
• Physostigmine is the antidote for antimuscarinic delirium but is contraindicated when the ECG shows QRS widening — that stem is a tricyclic overdose, and the answer is sodium bicarbonate.
• Atropine in organophosphate poisoning is titrated to drying of secretions, not to pupils or heart rate; pralidoxime must be given before enzyme aging becomes irreversible.
• Tyramine plus MAOI = hypertensive crisis (aged cheese, cured meats, red wine); selegiline is MAO-B selective at low dose and loses that selectivity as dose rises.
• The one association tested repeatedly: NMDA receptors require glutamate and glycine as co-agonists and are blocked by Mg2+ at resting potential — the basis for excitotoxicity in stroke and for memantine's use in Alzheimer disease.
• Distractor to avoid: flumazenil in a chronic benzodiazepine user precipitates refractory seizures; supportive airway management, not reversal, is the answer.